AntiEGFRnano inhibites proliferation and migration of estrogen-dependent Ishikawa cells of human endometrial cancer cell line.
- Author:
Zhen-yu DIAO
1
;
Wu-guang LU
;
Peng CAO
;
Yun-long HU
;
Xing ZHOU
;
Ping-ping XUE
;
Li SHEN
;
Hai-xiang SUN
Author Information
1. Drum Tower Hospital Affiliated to School of Medicine, Nanjing University, Nanjing, China.
- Publication Type:Journal Article
- MeSH:
Adenocarcinoma;
metabolism;
pathology;
Amino Acid Sequence;
Base Sequence;
Cell Line, Tumor;
Cell Movement;
drug effects;
Cell Proliferation;
drug effects;
Endometrial Neoplasms;
metabolism;
pathology;
Escherichia coli;
metabolism;
Estrogens;
metabolism;
Female;
Genetic Vectors;
Humans;
Plasmids;
Receptor, Epidermal Growth Factor;
genetics;
immunology;
Recombinant Proteins;
metabolism;
Single-Domain Antibodies;
genetics;
pharmacology
- From:
Acta Pharmaceutica Sinica
2012;47(10):1341-1346
- CountryChina
- Language:Chinese
-
Abstract:
Nanobody is a kind of antibody from camel, which misses light chain. Nanobody has the same antigen binding specificity and affinity as mAb. Moreover, because of its small molecular weight, high stability and easy preparation, nanobody has great value of biomedical applications. In this study, we successfully prepared highly pure antiEGFR nanobody in E.coli using genetic engineering techniques. Cell proliferation assay (CCK-8 assay) and migration experiments (cell scratch test and Transwell assay) indicated that the recombinant antiEGFRnano can significantly inhibit the proliferation and migration of endometrial cancer cells. These results provide a new way of thinking and methods for EGFR-targeted therapy of endometrial cancer.
